Terumo to Construct New Facilities at Its Vietnamese Factory -
15 Billion Yen Investment to Strengthen Interventional Therapeutic Related Production

February 26, 2019

TOKYO, JAPAN - February 26, 2019 - Terumo Corporation (TSE: 4543) today announced that it plans to construct a new building to house its third manufacturing facility in Vietnam. It expects construction to be completed in December 2020. The Company will also install additional production facilities to increase production at the current first and second buildings. The investment will total approximately 15 billion yen over 5 years, and as a result of this investment, production capacity is expected to double.

The Vietnamese factory, which started its operation in 2008, mainly produces products for interventional therapeutics, which it ships to: Europe, South America, and Asia - including China and India. The interventional therapeutics market is anticipated to grow rapidly especially in China and India, and Terumo intends to develop a production system that can meet demands in those regions.

Terumo has made "Strengthen Global Operations" as one of its key initiatives in carrying out its Mid- to Long-term Growth Strategy, and is therefore reinforcing production capacity and optimizing global production. In the interventional therapeutics field, the Company has strengthened its production system by developing production sites in: Shizuoka, Yamaguchi, and Gifu prefectures in Japan; and in the US, Belgium, Puerto Rico, Vietnam, and China globally.

As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world - by consistently providing "Total Quality": highest quality in all product, supply, and service.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

Print
T
O
P